Ingersoll Rand Inc. has announced the acquisition of Dave Barry Plastics, further enhancing its life sciences portfolio. This strategic move aligns with Ingersoll Rand's commitment to expanding its offerings with high-performance solutions. Dave Barry Plastics, based in Ireland, specializes in designing and manufacturing custom plastic products for the biopharmaceutical, pharmaceutical, and medical device industries. The acquisition is expected to bolster Ingersoll Rand's capabilities within the life sciences sector, particularly in providing solutions for clean rooms. The transaction was made at an attractive purchase multiple of approximately 9x 2024 Adjusted EBITDA, emphasizing Ingersoll Rand's strategy of growth through direct investments and strong relationships with family-owned businesses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.